172 related articles for article (PubMed ID: 25069718)
1. High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families.
Riahi A; Kharrat M; Lariani I; Chaabouni-Bouhamed H
Fam Cancer; 2014 Dec; 13(4):603-9. PubMed ID: 25069718
[TBL] [Abstract][Full Text] [Related]
2. Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.
Takano EA; Mitchell G; Fox SB; Dobrovic A
BMC Cancer; 2008 Feb; 8():59. PubMed ID: 18298804
[TBL] [Abstract][Full Text] [Related]
3. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
5. High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations.
de Juan I; Esteban E; Palanca S; Barragán E; Bolufer P
Breast Cancer Res Treat; 2009 May; 115(2):405-14. PubMed ID: 18528753
[TBL] [Abstract][Full Text] [Related]
6. A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes.
Hondow HL; Fox SB; Mitchell G; Scott RJ; Beshay V; Wong SQ; ; Dobrovic A
BMC Cancer; 2011 Jun; 11():265. PubMed ID: 21702907
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P
Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 Germline Mutation Screening in Western Algeria using High Resolution Melting Analysis (HRM).
Boulenouar ACS; Coulet F; Bendiab FMT; Boudinar FZ; Senhadji R
Gulf J Oncolog; 2018 May; 1(27):31-37. PubMed ID: 30145549
[TBL] [Abstract][Full Text] [Related]
9. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
11. Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers.
Jiménez Ide J; Esteban Cardeñosa E; Palanca Suela S; González EB; Bolufer Gilabert P;
Clin Biochem; 2009 Oct; 42(15):1572-6. PubMed ID: 19616529
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.
Tazzite A; Jouhadi H; Nadifi S; Aretini P; Falaschi E; Collavoli A; Benider A; Caligo MA
Gynecol Oncol; 2012 Jun; 125(3):687-92. PubMed ID: 22425665
[TBL] [Abstract][Full Text] [Related]
13. A one-step prescreening for point mutations and large rearrangement in BRCA1 and BRCA2 genes using quantitative polymerase chain reaction and high-resolution melting curve analysis.
Coulet F; Pires F; Rouleau E; Lefol C; Martin S; Colas C; Cohen-Haguenauer O; Giurgea I; Fajac A; Noguès C; Demange L; Hardouin A; Lidereau R; Soubrier F
Genet Test Mol Biomarkers; 2010 Oct; 14(5):677-90. PubMed ID: 20858050
[TBL] [Abstract][Full Text] [Related]
14.
Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
[TBL] [Abstract][Full Text] [Related]
16. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries.
Cherbal F; Bakour R; Adane S; Boualga K
Breast Dis; 2012; 34(1):1-8. PubMed ID: 23697973
[TBL] [Abstract][Full Text] [Related]
18. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
19. Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.
Hansen TV; Jønson L; Steffensen AY; Andersen MK; Kjaergaard S; Gerdes AM; Ejlertsen B; Nielsen FC
Fam Cancer; 2011 Jun; 10(2):207-12. PubMed ID: 21318380
[TBL] [Abstract][Full Text] [Related]
20. Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing.
Hernan I; Borràs E; de Sousa Dias M; Gamundi MJ; Mañé B; Llort G; Agúndez JA; Blanca M; Carballo M
J Mol Diagn; 2012; 14(3):286-93. PubMed ID: 22426013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
